Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS: We performed an in vivo kinetic study with stable isotopes (L-[1-13C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-containing lipoprotein clearance. RESULTS: In patients with T2D, liraglutide treatment significantly reduced plasma apoB100 (0.93 ± 0.13 vs. 1.09 ± 0.11 g/L, P = 0.011) and fasting triglycerides (1.76 ± 0.37 vs. 2.48 ± 0.69 mmol/L, P = 0.005). The kinetic study showed a significant increase in indirect catabolism of VLDL1-apoB100 (4.11 ± 1.91 vs. 2.96 ± 1.61 pools/day, P = 0.005), VLDL2-apoB100 (5.17 ± 2.53 vs. 2.84 ± 1.65 pools/day, P = 0.008), and IDL-apoB100 (5.27 ± 2.77 vs. 3.74 ± 1.85 pools/day, P = 0.017) and in catabolism of LDL-apoB100 (0.72 ± 0.22 vs. 0.56 ± 0.22 pools/day, P = 0.005). In mice, liraglutide increased lipoprotein lipase (LPL) gene expression and reduced proprotein convertase subtilisin/kexin type 9 (PCSK9), retinol-binding protein 4 (RBP4), and tumor necrosis factor-α (TNF-α) gene expression in adipose tissue and decreased PCSK9 mRNA and increased LDL receptor protein expression in liver. In vitro, liraglutide directly reduced the expression of PCSK9 in the liver. CONCLUSIONS: Treatment with liraglutide induces a significant acceleration of the catabolism of triglyceride-rich lipoproteins (VLDL1, VLDL2, IDL) and LDL. Liraglutide modifies the expression of genes involved in apoB100-containing lipoprotein catabolism. These positive effects on lipoprotein metabolism may reduce cardiovascular risk in T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro studies further showed that liraglutide directly reduced the expression of several genes involved in chylomicron production and of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene [40, 42].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [42]
In the citing paper
“Liraglutide has also been shown to significantly modify lipoprotein metabolism, with a reduction of chylomicron production [40, 41] and an increase in chylomicron and low-density lipoprotein (LDL) catabolism [40, 42].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [42]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo.
Semb, H., Peterson, J., Tavernier, J., & Olivecrona, T. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47576-x · Cited by 238
Inflammation stimulates the expression of PCSK9
Feingold, K. R., Moser, A. H., Shigenaga, J. K., Patzek, S. M., & Grunfeld, C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.023 · Cited by 228
Increase of adipose tissue lipoprotein lipase activity with weight loss.
Schwartz, R. S., & Brunzell, J. D. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110171 · Cited by 153
Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
Duvillard, L. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00702.x · Cited by 124
Self-citationRuscica, M., Ricci, C., Macchi, C., Magni, P., Cristofani, R., Liu, J., Corsini, A., & Ferri, N. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664706 · Cited by 109
Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM
Taskinen, M.-R., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diab.39.9.1017 · Cited by 107
Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97
Taher, J., Baker, C. L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausova, Z., & Adeli, K. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.005 · Cited by 90
Liu, J., Yang, K., Yang, J., Xiao, W., Le, Y., Yu, F., Gu, L., Lang, S., Tian, Q., Jin, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.037 · Cited by 85
Bułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., & Okopień, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.008 · Cited by 84
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 83
Millar, J. S., Maugeais, C., Ikewaki, K., Kolansky, D. M., Barrett, P. H. R., Budreck, E. C., Boston, R. C., Tada, N., Mochizuki, S., Defesche, J. C., et al. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000155323.18856.a2 · Cited by 78
Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Sberna, A.-L., Petit, J.-M., Degrace, P., & Demizieux, L. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310990 · Cited by 75
Self-citationDegrace, P., Moindrot, B., Mohamed, I., Gresti, J., Du, Z.-Y., Chardigny, J.-M., Sébédio, J.-L., & Clouet, P. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600140-jlr200 · Cited by 68
Self-citationOxidative Damage, Plasma Antioxidant Capacity, and Glucemic Control in Elderly NIDDM Patients
Aguirre, F., Martin, I., Grinspon, D., Ruiz, M. C., Hager, A., Paoli, T. D., Ihlo, J. E., Farach, H. A., & Poole, C. P. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(97)00293-1 · Cited by 66
von Scholten, B. J., Persson, F., Rosenlund, S., Eugen‐Olsen, J., Pielak, T., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12884 · Cited by 60
Yang, S., Xu, R., Cui, C.-J., Wang, Y., Du, Y., Chen, Z., Yao, Y., Ma, C., Zhu, C., Guo, Y., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0689-9 · Cited by 58
The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
Luo, M., & Peng, D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0352-y · Cited by 57
Duvillard, L., Pont, F., Florentin, E., Gambert, P., & Vergès, B. L. (2000) · Diabetologia · doi:10.1007/s001250050004 · Cited by 51
Self-citationInfluence of Atorvastatin on Apolipoprotein E and AI Kinetics in Patients with Type 2 Diabetes
Bach‐Ngohou, K., Ouguerram, K., Frénais, R., Maugère, P., Piquer, B. R., Zaïr, Y., Krempf, M., & Bard, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085522 · Cited by 33
Plutzky, J., Garber, A., Falahati, A., Toft, A. D., & Poulter, N. R. (2009) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(09)33072-5 · Cited by 33
Vergès, B. L., Guiu, B., Cercueil, J., Duvillard, L., Robin, I., Buffier, P., Bouillet, B., Aho, S., Brindisi, M., & Petit, J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.255190 · Cited by 33
Self-citationYokomori, H., & Ando, W. (2020) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2019-000370 · Cited by 33
Tremblay, A. J., Lamarche, B., Kelly, I., Charest, A., Lépine, M. ‐., Droit, A., & Couture, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12359 · Cited by 31
Apolipoprotein A-I, A-II, and VLDL-B-100 metabolism in men
Desroches, S., Paradis, M.-E., Pérusse, M., Archer, W. R., Bergeron, J., Couture, P., Bergeron, N., & Lamarche, B. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400287-jlr200 · Cited by 31
Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes
Vergès, B. L., Florentin, E., Baillot-Rudoni, S., Monier, S., Petit, J., Rageot, D., Gambert, P., & Duvillard, L. (2008) · Diabetologia · doi:10.1007/s00125-008-1046-4 · Cited by 27
Self-citationSahebkar, A., Simental-Mendía, L. E., Katsiki, N., Reiner, Ž., Banach, M., Pirro, M., & Atkin, S. L. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021508 · Cited by 25
Brackenridge, A., Jackson, N., Jefferson, W., Stolinski, M., Shojaee‐Moradie, F., Hovorka, R., Umpleby, A. M., & Russell-Jones, D. L. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02729.x · Cited by 15
Tremblay, A. J., Lamarche, B., Ruel, I. L., Hogue, J., Deshaies, Y., Gagné, C., & Couture, P. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.037 · Cited by 15
Yamaaki, N., Yagi, K., Kobayashi, J., Nohara, A., Ito, N., Asano, A., Nakano, K., Liu, J., Okamoto, T., Mori, Y., et al. (2013) · Journal of Diabetes Research · doi:10.1155/2013/143515 · Cited by 10
Cited by
Ghodsian, N., Abner, E., Emdin, C. A., Gobeil, É., Taba, N., Haas, M. E., Perrot, N., Manikpurage, H. D., Gagnon, É., Bourgault, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100437 · Cited by 229
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
“Treatment of 10 subjects with T2D (average age 48.6 years) with 1.2 mg liraglutide daily for 6 months reduced ApoB48 levels and ApoB48 production rate and enhanced the catabolic rate of ApoB48 (determined via D 8 -valine isotopes), findings independent of body weight loss (32, 33).”
InfluentialVergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“Liraglutide has also been shown to significantly modify lipoprotein metabolism, with a reduction of chylomicron production [40, 41] and an increase in chylomicron and low-density lipoprotein (LDL) catabolism [40, 42].”
BackgroundSelf-citationCherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Metadata
- Authors
- Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., & Demizieux, L.
- Affiliations
- Inserm (FR)
- INSERM LNC UMR1231, University of Burgundy, Dijon, France
- CHU Dijon Bourgogne (FR)
- Corresponding author
- Vergès, Bruno
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-02-02
- Volume
- 44
- Issue
- 4
- Pages
- 1027-1037
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3126193654
- Cited by
- 54
- References
- 45
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 8
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Agence Nationale de la Recherche (ANR-11-LABX-0021)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein B-100, lipoprotein catabolism, type 2 diabetes, diabetic dyslipidemia, GLP-1 receptor agonists, PCSK9, VLDL, IDL, low-density lipoprotein, triglyceride-rich lipoproteins, small dense LDL, lipoprotein clearance, atherogenic dyslipidemia
- MeSH terms
- Liraglutide, Proprotein Convertase 9, Animals, Diabetes Mellitus, Type 2, Humans, Lipoproteins, Lipoproteins, LDL, Lipoproteins, VLDL, Subtilisins, Mice, Retinol-Binding Proteins, Plasma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.